Radiother Oncol:电子束放疗的生物有效剂量对瘢痕疙瘩切除术后复发率的影响

2022-09-10 MedSci原创 MedSci原创

瘢痕疙瘩切除术后的辅助电子束放射治疗已被证明对减少局部复发非常有效。尽管对于瘢痕疙瘩术后RT的最佳剂量没有明确的共识,但我们认为大多数医院和中心都在使用低分量RT。

瘢痕疙瘩切除术后的辅助电子束放射治疗已被证明对减少局部复发非常有效。尽管对于瘢痕疙瘩术后RT的最佳剂量没有明确的共识,但我们认为大多数医院和中心都在使用低分量RT。为了比较不同的处方剂量,有必要将其转换成生物有效剂量(BED),这通常用于等效剂量的计算。近日,发表于Radiother Oncol的一项荟萃分析中,研究人员根据准确的辐射剂量信息对瘢痕疙瘩切除术后低分量电子束放射治疗的研究进行了分析,以更精确地估计BED对复发率的影响。

研究人员系统检索了PubMed、Embase和Cochrane图书馆在1990年至2021年12月期间收录的相关文献。选择提供确切处方剂量复发率信息的研究进行分析。使用森林图和散点图上的最佳拟合线来评估与BED有关的复发率。

 

结果,从纳入分析的28项研究中,研究人员共提取了37个辐射剂量数据集,确定了3128个切除的瘢痕疙瘩。分析结果显示,所有部位和耳朵部位瘢痕疙瘩的复发率分别为0.16(95%置信区间,0.12-0.21;P < 0.01)和0.11(95%置信区间,0.06-0.20;P < 0.01)。所有部位和耳朵部位瘢痕疙瘩的估计复发率分别计算为"-1.992+1018.226/BED2 "或 "2.982+330.51/BED10 "和"-16.8+1597.84/BED2 "或"-14.65+656.58/BED10"。

综上所述,该研究结果表明,术后放疗的BED较高,复发率较低。正如预期的那样,耳部瘢痕的估计复发率低于所有部位的所有瘢痕。研究人员提供了一个使用剂量分型方案来估计复发率的模型。

原始出处:

Na-Hyun Hwang, et al., Effect of the biologically effective dose of electron beam radiation therapy on recurrence rate after keloid excision: A meta-analysis. Radiother Oncol. 2022 Aug;173:146-153. doi: 10.1016/j.radonc.2022.06.003.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1967801, encodeId=dbdd196e8015d, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Apr 20 18:30:02 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866706, encodeId=cb621866e06b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 30 02:30:02 CST 2023, time=2023-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877610, encodeId=634b18e76106b, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Jul 15 12:30:02 CST 2023, time=2023-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922454, encodeId=82ac192245464, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Mon Aug 07 22:30:02 CST 2023, time=2023-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991860, encodeId=16381991860e6, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri Nov 11 23:30:02 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792962, encodeId=36ce1e92962b2, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 03 20:30:02 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337014, encodeId=50d1133e014dc, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sun Sep 11 03:30:02 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1967801, encodeId=dbdd196e8015d, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Apr 20 18:30:02 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866706, encodeId=cb621866e06b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 30 02:30:02 CST 2023, time=2023-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877610, encodeId=634b18e76106b, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Jul 15 12:30:02 CST 2023, time=2023-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922454, encodeId=82ac192245464, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Mon Aug 07 22:30:02 CST 2023, time=2023-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991860, encodeId=16381991860e6, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri Nov 11 23:30:02 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792962, encodeId=36ce1e92962b2, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 03 20:30:02 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337014, encodeId=50d1133e014dc, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sun Sep 11 03:30:02 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2023-07-30 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1967801, encodeId=dbdd196e8015d, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Apr 20 18:30:02 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866706, encodeId=cb621866e06b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 30 02:30:02 CST 2023, time=2023-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877610, encodeId=634b18e76106b, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Jul 15 12:30:02 CST 2023, time=2023-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922454, encodeId=82ac192245464, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Mon Aug 07 22:30:02 CST 2023, time=2023-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991860, encodeId=16381991860e6, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri Nov 11 23:30:02 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792962, encodeId=36ce1e92962b2, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 03 20:30:02 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337014, encodeId=50d1133e014dc, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sun Sep 11 03:30:02 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1967801, encodeId=dbdd196e8015d, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Apr 20 18:30:02 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866706, encodeId=cb621866e06b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 30 02:30:02 CST 2023, time=2023-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877610, encodeId=634b18e76106b, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Jul 15 12:30:02 CST 2023, time=2023-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922454, encodeId=82ac192245464, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Mon Aug 07 22:30:02 CST 2023, time=2023-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991860, encodeId=16381991860e6, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri Nov 11 23:30:02 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792962, encodeId=36ce1e92962b2, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 03 20:30:02 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337014, encodeId=50d1133e014dc, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sun Sep 11 03:30:02 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1967801, encodeId=dbdd196e8015d, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Apr 20 18:30:02 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866706, encodeId=cb621866e06b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 30 02:30:02 CST 2023, time=2023-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877610, encodeId=634b18e76106b, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Jul 15 12:30:02 CST 2023, time=2023-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922454, encodeId=82ac192245464, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Mon Aug 07 22:30:02 CST 2023, time=2023-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991860, encodeId=16381991860e6, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri Nov 11 23:30:02 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792962, encodeId=36ce1e92962b2, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 03 20:30:02 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337014, encodeId=50d1133e014dc, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sun Sep 11 03:30:02 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1967801, encodeId=dbdd196e8015d, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Apr 20 18:30:02 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866706, encodeId=cb621866e06b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 30 02:30:02 CST 2023, time=2023-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877610, encodeId=634b18e76106b, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Jul 15 12:30:02 CST 2023, time=2023-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922454, encodeId=82ac192245464, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Mon Aug 07 22:30:02 CST 2023, time=2023-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991860, encodeId=16381991860e6, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri Nov 11 23:30:02 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792962, encodeId=36ce1e92962b2, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 03 20:30:02 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337014, encodeId=50d1133e014dc, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sun Sep 11 03:30:02 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1967801, encodeId=dbdd196e8015d, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Apr 20 18:30:02 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866706, encodeId=cb621866e06b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 30 02:30:02 CST 2023, time=2023-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877610, encodeId=634b18e76106b, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Jul 15 12:30:02 CST 2023, time=2023-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922454, encodeId=82ac192245464, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Mon Aug 07 22:30:02 CST 2023, time=2023-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991860, encodeId=16381991860e6, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri Nov 11 23:30:02 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792962, encodeId=36ce1e92962b2, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 03 20:30:02 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337014, encodeId=50d1133e014dc, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sun Sep 11 03:30:02 CST 2022, time=2022-09-11, status=1, ipAttribution=)]

相关资讯

15种常见放疗危及器官限量参考标准

放疗时一定要注重正常组织和重要器官的保护!

放疗基础:放疗常用专业术语大全,随用随查

这些基础知识,你都了解吗?

ASCO指南又双叒有更新啦!HER2阳性晚期乳腺癌脑转移如何处理?一图看清!

J Clin Oncol:晚期人表皮生长因子受体2阳性乳腺癌和脑转移的处理:ASCO指南更新

Lancet Oncol:cT1-2N1乳腺癌初始化疗后可根据复发风险进行适应性的降级放疗

在这项研究中,所有乳腺癌患者的 5 年局部区域复发率低于 4%,支持了研究人员的假设,即在接受初次化疗的cT1-2N1期乳腺癌患者中,基于局部区域复发风险降低局部区域放疗剂量在肿瘤学上是安全的。

Lancet:非低风险乳腺导管原位癌的放疗剂量和分割方案

对于切除后的非低危乳腺导管原位癌患者,全乳放疗后对肿瘤床进行强化放疗可减少局部复发率